Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4586722 | 0.87 | KLKB1 (0.64) | KLKB1CARM1 | |
| SCHEMBL22967845 | 0.87 | KLKB1 (0.54) | KLKB1CARM1 | |
| SCHEMBL5698238 | 0.85 | KLKB1 (0.53) | KLKB1CARM1 | |
| SCHEMBL22417061 | 0.85 | CARM1 (0.59) | KLKB1CARM1 | |
| SCHEMBL18630201 | 0.85 | KLKB1 (0.52) | KLKB1CARM1 | |
| SCHEMBL23119709 | 0.84 | KLKB1 (0.43) | KLKB1CARM1 | |
| SCHEMBL21919181 | 0.84 | CARM1 (0.60) | KLKB1CARM1 | |
| SCHEMBL22416926 | 0.83 | CARM1 (0.73) | KLKB1CARM1 | |
| SCHEMBL21100671 | 0.83 | KLKB1 (0.43) | KLKB1CARM1 | |
| SCHEMBL22417105 | 0.82 | CARM1 (0.61) | KLKB1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3113772-B1 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10329260-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329260-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885CARM1 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.